

For patients with MDD,

IS PARTIAL RESPONSE GOOD ENOUGH?

Actor portrayal.

▄▄ I feel slightly better since switching antidepressants, but I'm still feeling down. I worry my performance is slipping at work, and that hopeless feeling is getting worse. Some days are okay, but others—I don't want to get out of bed. ▄▄

—Kimberly

OCCUPATION: Teacher, mother of two

AGE: 38

CURRENT MDD PRESENTATION OF THIS HYPOTHETICAL PATIENT:

- Partial response since switching from SSRI to SNRI, despite optimal dose/duration
- Current symptoms: pessimistic thoughts, ongoing sadness, excessive worry
- Expresses reluctance to switch antidepressants
- Symptoms of anxiety

Atypical antipsychotic drugs have been associated with metabolic changes including: hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain.

MDD, major depressive disorder; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

INDICATION

REXULTI® (brexpiprazole) is indicated for:

- Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.



Please see **IMPORTANT SAFETY INFORMATION** on pages 8 and 9.



When taken with an antidepressant,

Adding REXULTI® (brexpiprazole) amplified antidepressant symptom response vs placebo

Adult patients in the ADT + REXULTI 2 mg/day arm experienced a 62% greater reduction in MÅDRS total score¹



It is unknown if the differences observed at time points earlier than Week 6 represent clinically relevant treatment effects.

Mean MÅDRS before prospective treatment (SD): 31.0 (4.7). Mean MÅDRS after prospective treatment (SD): 27.1 (5.7). Mean MÅDRS at randomization (SD): ADT + placebo (n=178), 27.3 (5.6); ADT + REXULTI 2 mg/day (n=175), 26.9 (5.7).²

MDD STUDY DESIGN AND EFFICACY SUMMARY

REXULTI was studied in two 6-week, double-blind, placebo-controlled, fixed-dose pivotal trials of adult patients meeting DSM-IV-TR criteria for MDD. After a screening phase of 1-4 weeks, patients entered into an 8-week prospective treatment phase with an SSRI or SNRI. Subsequently, patients having persistent symptoms without substantial improvement throughout the course of treatment and who met inclusion criteria were randomized to receive adjunctive REXULTI or placebo.^{3,4}

Primary endpoint was the mean change from baseline to Week 6 in the MÅDRS total score in the randomization phase.^{3,4}

In the second pivotal trial, at the 3-mg/day maximum dose, the mean change from baseline (SE) at 6 weeks (randomized phase) was -8.3 (0.5) for ADT + REXULTI (n=213) vs -6.3 (0.5) for ADT + placebo (n=203), and the MÅDRS baseline (SD) for ADT + REXULTI and ADT + placebo was 26.5 (5.3) and 26.5 (5.2), respectively.⁴

The efficacy and safety of REXULTI were also studied in patients randomized to receive 1 mg/day in Study 2 (n=211). Results for the ADT + REXULTI 1-mg group for the primary efficacy parameter were not statistically significant when compared with ADT + placebo.⁴ ADT, antidepressant treatment; DSM IV-TR, Diagnostic and Statistical Manual of Mental Disorders; MÅDRS, Montgomery-Åsberg Depression Rating Scale; SD, standard deviation; SE, standard error.

Contraindication

In patients with known hypersensitivity to brexpiprazole or any of its components. Reactions have included: rash, facial swelling, urticaria and anaphylaxis.




Post-hoc analysis

REXULTI® (brexpiprazole) + ADT change in MÅDRS total score in adult patients with MDD—with or without symptoms of anxiety

Using pooled data from 3 similarly designed 6-week randomized studies, including both 2-mg and 3-mg doses, changes were evaluated in MÅDRS total score in patients with MDD—with and without symptoms of anxiety.^{3-5,a,b}

Effect on MÅDRS total score in patients with MDD, stratified by the presence or absence of symptoms of anxiety at baseline:



Study limitations: These analyses did not assess the effect of treatment on symptoms of anxiety. Patients with anxiety symptoms had a higher MÅDRS total score at baseline and the effects of anxiety and illness severity on outcomes were not differentiated. Statistical adjustments were not made for multiple comparisons, potentially inflating the type 1 error rate.

Adding REXULTI reduced mean MÅDRS total score by over 2 points in patients with MDD with or without symptoms of anxiety:

- ▶ For patients with symptoms of anxiety, the LS mean change at Week 6 between ADT + REXULTI 2-3 mg/day and ADT + placebo was -2.19 (95% CI: -3.60, -0.78)⁵
- ▶ For patients without symptoms of anxiety, the LS mean change at Week 6 between ADT + REXULTI 2-3 mg/day and ADT + placebo was -2.34 (95% CI: -3.58, -1.10)⁵

^aBaseline demographics and clinical characteristics were similar between treatment subgroups; however, patients with symptoms of anxiety were more likely to be female and have a higher MÅDRS total score at baseline compared with patients without symptoms of anxiety.⁵

^bOf the patients that received an ADT plus REXULTI 2 mg, 3 mg, or placebo, 49% had symptoms of anxiety, defined as a score of ≥ 7 at baseline on the HAM-D anxiety somatization factor.⁵
CI, confidence interval; HAM-D, Hamilton Rating Scale for Depression; LS, least squares.

Important Warning and Precaution for Cerebrovascular Adverse Events, Including Stroke

In clinical trials, elderly patients with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.



REXULTI® (brexpiprazole) + antidepressants: safety profile in adult patients with MDD

Adverse reactions that occurred in $\geq 2\%$ of patients and with greater incidence than placebo from two 6-week pivotal trials across all doses

Rates for ADT^a + REXULTI (all doses; n=643) vs ADT^a + placebo (n=411)

| | | | | | |
|--------------------|------------|-----------------------|----------|----------------------------|----------|
| ▪ Akathisia: | 9% vs 2% | ▪ Tremor: | 4% vs 2% | ▪ Restlessness: | 3% vs 0% |
| ▪ Headache: | 7% vs 6% | ▪ Fatigue: | 3% vs 2% | ▪ Blood cortisol decrease: | 2% vs 1% |
| ▪ Weight increase: | 7% vs 2% | ▪ Increased appetite: | 3% vs 2% | ▪ Constipation: | 2% vs 1% |
| ▪ Somnolence: | 5% vs 0.5% | ▪ Anxiety: | 3% vs 1% | | |
| ▪ Nasopharyngitis: | 4% vs 2% | ▪ Dizziness: | 3% vs 1% | | |

The **most common adverse reactions** ($\geq 5\%$) and at least twice the rate of placebo for ADT + REXULTI vs ADT + placebo were weight increased (7% vs 2%), somnolence (5% vs 0.5%), and akathisia (9% vs 2%).

Two adverse reactions were dose-dependent

| | ADT + REXULTI (n=643) | | | ADT + Placebo (n=411) |
|---------------------|--------------------------|---------------|---------------|--------------------------|
| | 1 mg n=226 | 2 mg n=188 | 3 mg n=229 | |
| Akathisia | 4% | 7% | 14% | 2% |
| Restlessness | 2% | 3% | 4% | 0% |

► A majority of the akathisia cases reported were mild or moderate⁶

^aThe antidepressants studied included SSRIs and SNRIs.

The safety population included patients randomized between 1 mg/day and 3 mg/day of ADT + REXULTI.




Important Warning and Precaution for Neuroleptic Malignant Syndrome (NMS)

NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs, including REXULTI. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.



REXULTI® (brexpiprazole) + antidepressants: few discontinuations due to adverse reactions over 6 weeks across all doses

Discontinuation rates for antidepressant treatment + REXULTI
vs antidepressant treatment + placebo




In patients taking ADT + REXULTI (n=643, all doses) vs ADT + placebo (n=411), the rate of discontinuation due to akathisia was 0.9% vs 0% and the rate of discontinuation due to weight gain was 0% vs 0%, respectively^{7,8}

Important Warning and Precaution for Tardive Dyskinesia (TD)

Risk of TD, and the potential to become irreversible, appear to increase with duration of treatment and total cumulative dose of antipsychotic drugs. TD can develop after relatively brief treatment periods, at low doses, or after discontinuation of treatment. For chronic treatment, use the lowest dose and shortest duration of REXULTI needed to produce a clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered.

REXULTI® (brexpiprazole): dosing and titration schedule

REXULTI—recommended target dose: 2 mg/day



- ▶ Dose increases should occur at weekly intervals based on the patient's clinical response and tolerability, and should be periodically reassessed to determine the continued need and appropriate dose for treatment

2 mg/day

Recommended dose

1 /day

Once-daily dosing

No food requirements



4-hour peak plasma concentration
(after administration)



Half-life

Dose adjustments for REXULTI

- ▶ Dose adjustments may be needed in patients with hepatic or renal impairment
- ▶ Administer half the dose of REXULTI when taken with strong CYP3A4 inhibitors or in patients who are known CYP2D6 poor metabolizers
- ▶ Administer a quarter of the dose with the concurrent use of both strong/moderate CYP2D6 inhibitors and strong/moderate CYP3A4 inhibitors. Likewise, administer a quarter of the dose in patients who are known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors
- ▶ Double the dose over 1 to 2 weeks when administering with strong CYP3A4 inducers

Savings and Coverage

The REXULTI Savings Card offers **TWO** separate benefits:
REXULTI® (brexpiprazole) as well as a **generic ANTIDEPRESSANT^a**



REXULTI

Two Months of REXULTI as little as \$0 ✓

REXULTI Refills as little as \$5 ✓

90-day Prescription as little as \$5 ✓


Generic ANTIDEPRESSANT

Generic ANTIDEPRESSANTS
as little as^b \$0 ✓

^aFor eligible commercially insured patients who are prescribed REXULTI. Benefits apply to copays, co-insurance, and pharmacy deductibles. Maximum annual benefit applies based on current list price. See full Terms & Conditions at www.REXULTI.com/savings-card-terms-conditions for the current maximum benefit and more information.

^bFor up to 12 uses.

REXULTI has broad national coverage and affordability support

97% 
OF PATIENTS NATIONALLY
have **COVERAGE** for REXULTI⁹



Helpful support resources for your patients are available at
REXULTI.com—including the REXULTI Savings Card and My Wellness Guide.

Please see **IMPORTANT SAFETY INFORMATION** on pages 8 and 9.

References: 1. Data on file (REX-014). 2. Data on file (REX-284). 3. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. *J Clin Psychiatry*. 2015;76(9):1224-1231. 4. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. *J Clin Psychiatry*. 2015;76(9):1232-1240. 5. Thase ME, Weiller E, Zhang P, Weiss C, McIntyre RS. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. *Neuropsychiatr Dis Treat*. 2019;15:37-45. 6. Weiss C, Skuban A, Hobart M, Zhang P, Weiller E. Incidence, onset, duration and severity of akathisia with adjunctive brexpiprazole (OPC-34712) in major depressive disorder: analysis of two pivotal studies. Poster presented at: American Society of Clinical Psychopharmacology Annual Meeting; June 22-25, 2015; Miami, FL. 7. Data on file (REX-022). 8. Data on file (REX-034). 9. Managed Markets Insights & Technology/Precision. Accessed July 2021.



IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

Contraindication: In patients with known hypersensitivity to brexpiprazole or any of its components. Reactions have included: rash, facial swelling, urticaria and anaphylaxis.

Cerebrovascular Adverse Events, Including Stroke: In clinical trials, elderly patients with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs, including REXULTI. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): Risk of TD, and the potential to become irreversible, appear to increase with duration of treatment and total cumulative dose of antipsychotic drugs. TD can develop after relatively brief treatment periods, at low doses, or after discontinuation of treatment. For chronic treatment, use the lowest dose and shortest duration of REXULTI needed to produce a clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered.

Metabolic Changes: Atypical antipsychotic drugs, including REXULTI, have caused metabolic changes including:

- **Hyperglycemia/Diabetes Mellitus:** Hyperglycemia and diabetes mellitus, in some cases extreme and associated with diabetic ketoacidosis, hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication and monitor periodically during long-term treatment.
- **Dyslipidemia:** Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.
- **Weight Gain:** Weight gain has been observed in patients treated with REXULTI. Monitor weight at baseline and frequently thereafter.

Pathological Gambling and Other Compulsive Behaviors: Intense urges, particularly for gambling, and the inability to control these urges have been reported while taking REXULTI. Other compulsive urges have been reported less frequently. Prescribers should ask patients or their caregivers about the development of new or intense compulsive urges. Consider dose reduction or stopping REXULTI if such urges develop.

(continued)

IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole) (continued)

Leukopenia, Neutropenia, and Agranulocytosis:

Leukopenia and neutropenia have been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in this class. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue REXULTI at the first sign of a clinically significant decline in WBC and in patients with severe neutropenia.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. Monitor in patients vulnerable to hypotension, and those with cardiovascular and cerebrovascular diseases.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor, and sensory instability, which may lead to falls causing fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: REXULTI may cause seizures and should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Body Temperature Dysregulation: Use REXULTI with caution in patients who may experience conditions that increase body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotics, including REXULTI, and should be used with caution in patients at risk for aspiration.

Potential for Cognitive and Motor Impairment:

REXULTI has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including operating motor vehicles, until they are reasonably certain REXULTI does not affect them adversely.

Concomitant Medication: Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers.

Most commonly observed adverse reactions: In clinical trials of adults, the most common adverse reactions were:

- **Major Depressive Disorder (MDD)** (adjunctive treatment to antidepressant therapy; $\geq 5\%$ incidence and at least twice the rate of placebo for REXULTI vs. placebo): weight increased, somnolence, and akathisia.

Dystonia: Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy: Adequate and well-controlled studies to assess the risks of REXULTI during pregnancy have not been conducted. REXULTI should be used during pregnancy only if the benefit justifies the risk to the fetus.

Lactation: It is not known if REXULTI is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Adding REXULTI® (brexpiprazole) to an ADT amplified antidepressant symptom response vs placebo, with a 62% greater reduction in MADRS total score

ADT + placebo

VS

ADT + REXULTI
2 mg/day

62% greater reduction in MADRS total score with ADT + REXULTI¹

LS mean change from baseline in MADRS total score:

- ▶ **2 mg/day recommended dose (SE):** -5.2 (0.6) for ADT + placebo vs -8.4 (0.6) for ADT + REXULTI³
- ▶ **3 mg/day maximum dose (SE):** -6.3 (0.5) for ADT + placebo vs -8.3 (0.5) for ADT + REXULTI⁴

| | ADT + REXULTI (all doses) | ADT + Placebo |
|-----------------|------------------------------|---------------|
| Weight increase | 7% | 2% |
| Somnolence | 5% | 0.5% |
| Akathisia | 9% | 2% |

- ▶ The table above presents the most common adverse reactions that occurred in ≥5% of patients and at least twice the rate of placebo



Once you recognize partial response on an antidepressant, consider adding REXULTI

REXULTI was studied in two 6-week, double-blind, placebo-controlled, fixed-dose pivotal trials of adult patients meeting DSM-IV-TR criteria for MDD. After a screening phase of 1-4 weeks, patients entered into an 8-week prospective treatment phase with an SSRI or SNRI. Subsequently, patients having persistent symptoms without substantial improvement throughout the course of treatment and who met inclusion criteria were randomized to receive adjunctive REXULTI or placebo.^{3,4}

INDICATION

REXULTI is indicated for:

- Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

Please see [IMPORTANT SAFETY INFORMATION](#) on pages 8 and 9.

